JP2018064568A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018064568A5 JP2018064568A5 JP2017223489A JP2017223489A JP2018064568A5 JP 2018064568 A5 JP2018064568 A5 JP 2018064568A5 JP 2017223489 A JP2017223489 A JP 2017223489A JP 2017223489 A JP2017223489 A JP 2017223489A JP 2018064568 A5 JP2018064568 A5 JP 2018064568A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- truncated
- nucleic acid
- composition according
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 13
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 238000003782 apoptosis assay Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000005522 programmed cell death Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562126804P | 2015-03-02 | 2015-03-02 | |
| US62/126,804 | 2015-03-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546893A Division JP6336684B2 (ja) | 2015-03-02 | 2016-03-01 | Ｐｄ−ｌ１によって誘導される免疫寛容の低減 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018064568A JP2018064568A (ja) | 2018-04-26 |
| JP2018064568A5 true JP2018064568A5 (cg-RX-API-DMAC7.html) | 2019-02-21 |
| JP6767347B2 JP6767347B2 (ja) | 2020-10-14 |
Family
ID=56848306
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546893A Active JP6336684B2 (ja) | 2015-03-02 | 2016-03-01 | Ｐｄ−ｌ１によって誘導される免疫寛容の低減 |
| JP2017223489A Active JP6767347B2 (ja) | 2015-03-02 | 2017-11-21 | Ｐｄ−ｌ１によって誘導される免疫寛容の低減 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546893A Active JP6336684B2 (ja) | 2015-03-02 | 2016-03-01 | Ｐｄ−ｌ１によって誘導される免疫寛容の低減 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US9572837B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3089761B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6336684B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102133857B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN107073138B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016228080B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017018770A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2976684C (cg-RX-API-DMAC7.html) |
| RU (1) | RU2688692C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201706947TA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016138846A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014100615A1 (en) | 2012-12-20 | 2014-06-26 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| WO2016126213A1 (en) * | 2015-02-06 | 2016-08-11 | National University Of Singapore | Methods for enhancing efficacy of therapeutic immune cells |
| AU2016228080B2 (en) | 2015-03-02 | 2020-11-12 | Innovative Cellular Therapeutics Holdings, Ltd. | Reducing immune tolerance induced by PD-L1 |
| IL255697B2 (en) | 2015-05-18 | 2023-11-01 | Tcr2 Therapeutics Inc | Compositions and methods for TCR programming using fusion proteins |
| CA2997551A1 (en) | 2015-09-04 | 2017-03-09 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| AU2016366226B2 (en) | 2015-12-09 | 2023-06-01 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of using same |
| JP7250519B2 (ja) * | 2016-03-23 | 2023-04-03 | ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー） | Ｐｄ－１及び４－１ｂｂの融合タンパク質 |
| US10654934B2 (en) | 2016-04-01 | 2020-05-19 | Innovative Cellular Therapeutics CO., LTD. | Use of chimeric antigen receptor modified cells to treat cancer |
| CN113082201B (zh) | 2016-04-01 | 2024-07-05 | 上海斯丹赛生物技术有限公司 | 刺激t细胞介导的对表达抗原的细胞群的免疫应答的方法 |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| CN109715668A (zh) | 2016-08-02 | 2019-05-03 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重编程的组合物和方法 |
| CN109863242A (zh) | 2016-08-30 | 2019-06-07 | 纪念斯隆-凯特林癌症中心 | 用于治疗病毒感染和其它感染的免疫细胞组合物和使用方法 |
| WO2018064921A1 (en) * | 2016-10-06 | 2018-04-12 | Innovative Cellular Therapeutics CO., LTD. | Use of chimeric antigen receptor modified cells to treat cancer |
| IL292551B2 (en) | 2016-10-07 | 2023-10-01 | Tcr2 Therapeutics Inc | Preparations and methods for reprogramming T-cell receptors using fusion proteins |
| JP7778468B2 (ja) | 2016-11-22 | 2025-12-02 | ナショナル ユニバーシティ オブ シンガポール | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
| AU2017363311A1 (en) | 2016-11-22 | 2019-06-13 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| CN108148862B (zh) * | 2016-12-05 | 2019-03-08 | 上海优卡迪生物医药科技有限公司 | 一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用 |
| WO2018104473A1 (en) | 2016-12-07 | 2018-06-14 | Oslo Universitetssykehus Hf | Compositions and methods for cell therapy |
| EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
| CN110582288B (zh) | 2017-02-28 | 2024-09-20 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
| EP3592368A1 (en) * | 2017-03-08 | 2020-01-15 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| KR20240059648A (ko) | 2017-04-19 | 2024-05-07 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 조작된 항원 수용체를 발현하는 면역 세포 |
| US20190038733A1 (en) | 2017-08-10 | 2019-02-07 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
| CN111433354A (zh) * | 2017-09-26 | 2020-07-17 | 朗沃德大学 | 作为免疫疗法的pd1特异性嵌合抗原受体 |
| CN109836493A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种靶向cd19的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| US10561686B2 (en) * | 2018-01-12 | 2020-02-18 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| CN112055595B (zh) | 2018-01-22 | 2024-12-17 | 恩多塞特公司 | Car t细胞的使用方法 |
| CA3090089A1 (en) | 2018-02-06 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| CN111918661A (zh) | 2018-02-21 | 2020-11-10 | 得克萨斯大学体系董事会 | 用于活化和扩增自然杀伤细胞的方法及其用途 |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| US12129485B2 (en) | 2018-05-23 | 2024-10-29 | National University Of Singapore | Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| US20210379149A1 (en) * | 2018-10-25 | 2021-12-09 | Innovative Cellular Therapeutics Holdings, Ltd. | Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy |
| US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| WO2020116686A1 (ko) * | 2018-12-06 | 2020-06-11 | 고려대학교 산학협력단 | 인간 항-antxr 키메라 항원 수용체 및 이의 용도 |
| CN109971842A (zh) * | 2019-02-15 | 2019-07-05 | 成都美杰赛尔生物科技有限公司 | 一种检测CRISPR-Cas9脱靶效应的方法 |
| US20220088074A1 (en) * | 2019-02-21 | 2022-03-24 | Regents Of The University Of Minnesota | Genetically modified gamma delta t cells and methods of making and using |
| CA3129862A1 (en) * | 2019-03-01 | 2020-09-10 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a pd-1 ectodomain |
| JP2022531814A (ja) * | 2019-03-12 | 2022-07-12 | イノベイティブ セルラー セラピューティクス ホールディングス，エルティディ | 改変細胞の増幅およびその応用 |
| US11739136B2 (en) * | 2019-03-18 | 2023-08-29 | Innovative Cellular Therapeutics Holdings, Ltd. | Inducible dominant negative PD-1 and uses in adoptive cell therapy |
| CN109868263A (zh) * | 2019-03-29 | 2019-06-11 | 深圳精准医疗科技有限公司 | 重组单纯疱疹病毒及其制备方法和应用、重组载体的构建方法及其应用 |
| CN114585641B (zh) * | 2019-05-16 | 2025-05-23 | 纪念斯隆-凯特琳癌症中心 | 间皮素car及其用途 |
| CN110423767A (zh) * | 2019-07-12 | 2019-11-08 | 华东师范大学 | 表达可溶性pd-1的嵌合抗原受体car基因及应用 |
| CN110592140A (zh) * | 2019-09-30 | 2019-12-20 | 王清路 | Pd-1基因缺陷型pd-1-cart细胞制剂的制法 |
| US20210137983A1 (en) * | 2019-11-08 | 2021-05-13 | Innovative Cellular Therapeutics Holdings, Ltd. | Nk cell expansion and uses thereof |
| EP4491235A3 (en) * | 2019-11-26 | 2025-03-26 | ImmunityBio, Inc. | Primary nk car constructs and methods |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| JP7198302B2 (ja) * | 2021-03-08 | 2022-12-28 | 一般財団法人 化学物質評価研究機構 | Ｐｄ－１を介した免疫チェックポイント阻害剤の生物活性試験法 |
| US20230227779A1 (en) | 2022-01-19 | 2023-07-20 | Innovative Cellular Therapeutics Holdings, Ltd. | Enhanced Chimeric Antigen Receptor Cells in Hypoxic Tumor Microenvironment |
| WO2025184170A1 (en) * | 2024-02-27 | 2025-09-04 | Overt Bio, Inc. | Methods and compositions for improving t cell function in an immunosuppressive environment |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| AU2002362273A1 (en) * | 2001-09-07 | 2003-03-24 | Everygene Ab | Polymorphisms of pd-1 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CN114835823A (zh) * | 2011-07-29 | 2022-08-02 | 宾夕法尼亚大学董事会 | 转换共刺激受体 |
| JP6074435B2 (ja) * | 2011-10-26 | 2017-02-01 | ナショナル キャンサー センター | 変異ｃｔｌａ４遺伝子移入ｔ細胞及びこれを含む抗がん免疫治療用組成物 |
| JP6850528B2 (ja) * | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| JP6463672B2 (ja) * | 2012-05-25 | 2019-02-06 | セレクティスＣｅｌｌｅｃｔｉｓ | Ｔｃｒアルファ欠損ｔ細胞を増殖させるためのプレｔアルファまたはその機能性変種の使用 |
| JP6401704B2 (ja) * | 2012-10-10 | 2018-10-10 | サンガモ セラピューティクス， インコーポレイテッド | Ｔ細胞を修飾する化合物およびその使用 |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| EP3811954A1 (en) * | 2013-02-26 | 2021-04-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
| ES2769574T3 (es) * | 2013-03-15 | 2020-06-26 | Michael C Milone | Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva |
| US10047137B2 (en) | 2013-04-05 | 2018-08-14 | Versitech Limited | Antibodies against novel PD1 isoforms and uses thereof |
| KR102164455B1 (ko) | 2013-05-08 | 2020-10-13 | 삼성전자주식회사 | 콘텐트 제공 방법, 콘텐트 제공 장치 및 그 콘텐트 제공 시스템 |
| AU2014262469B2 (en) * | 2013-05-10 | 2019-11-14 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| EP3811970A1 (en) | 2014-03-15 | 2021-04-28 | Novartis AG | Regulatable chimeric antigen receptor |
| US20170335281A1 (en) | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| PT3177640T (pt) * | 2014-08-08 | 2020-08-31 | Univ Leland Stanford Junior | Agentes pd-1 de alta afinidade e métodos de utilização |
| AU2016228080B2 (en) | 2015-03-02 | 2020-11-12 | Innovative Cellular Therapeutics Holdings, Ltd. | Reducing immune tolerance induced by PD-L1 |
| US10493139B2 (en) | 2015-07-24 | 2019-12-03 | Innovative Cellular Therapeutics CO., LTD. | Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor |
| CA2997551A1 (en) | 2015-09-04 | 2017-03-09 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| EP3362074B1 (en) | 2015-10-16 | 2023-08-09 | President and Fellows of Harvard College | Regulatory t cell pd-1 modulation for regulating t cell effector immune responses |
| AU2016366226B2 (en) | 2015-12-09 | 2023-06-01 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of using same |
| WO2019140100A1 (en) | 2018-01-11 | 2019-07-18 | Innovative Cellular Therapeutics Inc. | Modified cell expansion and uses thereof |
| US20210379149A1 (en) | 2018-10-25 | 2021-12-09 | Innovative Cellular Therapeutics Holdings, Ltd. | Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy |
-
2016
- 2016-03-01 AU AU2016228080A patent/AU2016228080B2/en not_active Ceased
- 2016-03-01 CN CN201680002926.1A patent/CN107073138B/zh active Active
- 2016-03-01 RU RU2017130985A patent/RU2688692C2/ru active
- 2016-03-01 KR KR1020177027722A patent/KR102133857B1/ko active Active
- 2016-03-01 CN CN201810281004.XA patent/CN108410892B/zh active Active
- 2016-03-01 EP EP16717825.0A patent/EP3089761B1/en active Active
- 2016-03-01 BR BR112017018770-1A patent/BR112017018770A2/pt not_active Application Discontinuation
- 2016-03-01 JP JP2017546893A patent/JP6336684B2/ja active Active
- 2016-03-01 CA CA2976684A patent/CA2976684C/en active Active
- 2016-03-01 WO PCT/CN2016/075061 patent/WO2016138846A1/en not_active Ceased
- 2016-03-01 EP EP19172425.1A patent/EP3549612B1/en active Active
- 2016-03-01 SG SG11201706947TA patent/SG11201706947TA/en unknown
- 2016-04-07 US US15/093,643 patent/US9572837B2/en active Active
- 2016-12-08 US US15/373,012 patent/US10619136B2/en active Active
-
2017
- 2017-11-21 JP JP2017223489A patent/JP6767347B2/ja active Active
-
2019
- 2019-05-06 US US16/404,349 patent/US10865382B2/en active Active
-
2020
- 2020-11-23 US US17/101,780 patent/US11932873B2/en active Active